insulin secretagogues peptides (incretins)

     

Select            
Trial Studied trt Control trt patientstagsROB Trial result

diabetes type 2

albiglutide
Seino, 2009      NCTalbiglutideplaceboExploratory negative
Rosenstock (30 mg every two weeks), 2009      NCTalbiglutide biweeklyplacebo (add on MET)Low risk of bias suggesting
Rosenstock (30 mg weekly), 2009      NCTalbiglutide weeklyplacebo (add on MET)Exploratory suggesting
exenatide
NCT00360334    NCTexenatideglarginenegative
Derosa, 2010     exenatide 20µgglibenclamidenegative
Liutkus, 2010     exenatideplacebonegative
H8O-MC-GWBJ, 9698, 10µg/d, 2008   exenatide 10µg/dplaceboLow risk of bias -
H8O-MC-GWBJ, 9698, 20µg/d, 2008   exenatide 20µg/dplaceboLow risk of bias -
Apovian, 2010     exenatide 20µg/dplaceboLow risk of bias negative
Moretto (DOUBLONS avec druker), 2008      NCTexenatide other dosesplaceboLow risk of bias negative
NCT00085969    NCTexenatide other dosesplaceboLow risk of bias -
Poon, 2005        NCTexenatide other dosesplaceboLow risk of bias -
Buse, 2011      NCTexenatide 20µg/dplacebo (add on insulin)Low risk of bias negative
Fineman, 2003     exenatide other dosesplacebo (add on MER+/-SU)Exploratory -
DeFronzo 10µg/d, 2005          NCTexenatide 10µg/dplacebo (add on MET)Low risk of bias negative
DeFronzo 20µg/d, 2005      NCTexenatide 20µg/dplacebo (add on MET)Low risk of bias suggesting
Kim, 2007      NCTexenatide weeklyplacebo (add on MET)Exploratory negative
Gao, 2009      NCTexenatide 20µg/dplacebo (add on MET+/-SU)Low risk of bias suggesting
Buse 10µg/d, 2004          NCTexenatide 10µg/dplacebo (add on SU)negative
Buse 20µg/d, 2004     exenatide 20µg/dplacebo (add on SU) -
Kadowaki (trial 8683), 2009     exenatide 10µg/dplacebo (add on SU+/-MET/TZD)Exploratory negative
Kendall 10µg/d, 2005      NCTexenatide 10µg/dplacebo (add on SU+MET)Low risk of bias negative
Kendall 20µg/d, 2005      NCTexenatide 20µg/dplacebo (add on SU+MET)Low risk of bias suggesting
Zinman 20µg/j, 2007    NCTexenatide 20µg/dplacebo (add on TZD+/-MET)Low risk of bias suggesting
Zinman 20µg/j A MODIFIER, 2007   exenatide 20µg/dplacebo (add on TZD+/-MET)Low risk of bias -
Gill, 2010     exenatide 10µg/dplacebo add on MET+/-TZDLow risk of bias negative
phase 2 exenatide once monthly   exenatide once monthlyweekly exenatide -
Bergenstal (once daily), 2009     exenatide 20µg/dBIAsp 30 dailyRisk of bias -
Bergenstal (twice daily), 2009     exenatide 20µg/dBIAsp 30 twice dailyRisk of bias negative
Exenatide Trial 10749   exenatide before lunch and dinnerexenatide before breakfast and dinnerRisk of bias -
HEELA (Davies), 2009   exenatide other dosesglargine -
Heine, 2005   exenatide 20µg/dinsulin (add on SU+MET)negative
Davis, 2007      NCTexenatide 20µg/dinsulin (add on SU/MET)Risk of bias negative
Barnett, 2007      NCTexenatide 20µg/dinsulin (add on SU/MET)Exploratory suggesting
Nauck, 2007      NCTexenatide 20µg/dinsulin BIAsp twice daily add on SU+METRisk of bias negative
DURATION-3 (Diamant), 2010    NCTexenatide weeklyinsulin glargineRisk of bias suggesting
Bunck, 2009          NCTexenatide 20µg/dinsulin glargine (add on MET)Exploratory -
Trial 8078   exenatide other dosesinsulin glargine (add on MET/SU) -
LEAD 6 (Buse) exe vs lira, 2009     exenatide 10µg twice dailyliraglutide 1.8mg -
DURATION-2 (Bergenstal) (vs pioglitazone), 2010      NCTexenatide weeklypioglitazoneLow risk of bias suggesting
DeFronzo (EXE vs ROSI), 2010     exenatide 20µg/drosiglitazone add on METExploratory negative
DURATION-2 (Bergenstal) (vs sitagliptin), 2010      NCTexenatide weeklysitagliptinLow risk of bias suggesting
DeFronzo, 2008      NCTexenatide 20µg/dsitagliptin (add on MET)Low risk of bias -
Drucker, 2008      NCTexenatide 20µg/dweekly exenatide -
liraglutide
NN2211-1333     liraglutide other doses -
Pratley (1.8 vs 1.2), 2010   liraglutide 1.8mgliraglutide 1.2mgnegative
LEADER, 2016      NCTliraglutideplaceboLow risk of bias conclusive
Seino, 2008      NCTliraglutide other dosesplaceboExploratory negative
Madsbad (vs placebo), 2004     liraglutide other dosesplacebonegative
Harder, 2004     liraglutide other dosesplaceboExploratory -
NN2211-1571 (Vilsbøll), 2007        NCTliraglutide other dosesplaceboExploratory negative
Kaku 0.6mg, 2010     liraglutide other dosesplaceboLow risk of bias suggesting
LEAD-2 (Nauck) (1.2mg vs placebo), 2009        NCTliraglutide 1.2mgplacebo (add on MET)Low risk of bias suggesting
LEAD-2 (Nauck) (1.8mg vs placebo), 2009      NCTliraglutide 1.8mgplacebo (add on MET)Low risk of bias suggesting
NN2211-1796      NCTliraglutide other dosesplacebo (add on MET) -
LEAD-1 SU (1.2 mg vs placebo), 2009        NCTliraglutide 1.2mgplacebo (add on SU)Low risk of bias suggesting
LEAD-1 SU (1.8 mg vs placebo), 2009      NCTliraglutide 1.8mgplacebo (add on SU)Low risk of bias suggesting
LEAD-5 (vs placebo), 2009      NCTliraglutide 1.8mgplacebo (add on SU+MET)Low risk of bias suggesting
LEAD-4 (1.2mg), 2009      NCTliraglutide 1.2mgplacebo (add on TZD+MET)Low risk of bias suggesting
LEAD-4 (1.8mg), 2009      NCTliraglutide 1.8mgplacebo (add on TZD+MET)Low risk of bias suggesting
Kaku 0.9mg, 2010     liraglutide other dosesplacebo (on top SU)Low risk of bias suggesting
LEAD-6, 2009        NCTliraglutide 1.8mgexenatide on top MET/SU/MET+SURisk of bias suggesting
Seino, 2010      NCTliraglutide other dosesglibenclamideLow risk of bias negative
LEAD-3 mono 1.2mg (Garber), 2009          NCTliraglutide 1.2mgglimepirideLow risk of bias negative
LEAD-3 mono 1.8mg (Garber), 2009      NCTliraglutide 1.8mgglimepirideLow risk of bias negative
Madsbad (vs Glimepiride), 2004     liraglutide other dosesglimepirideExploratory suggesting
LEAD-2 (Nauck) (1.2 mg vs glimepiride), 2009        NCTliraglutide 1.2mgglimepiride (add on MET)Low risk of bias negative
LEAD-2 (Nauck) (1.8 mg vs glimepiride), 2009      NCTliraglutide 1.8mgglimepiride (add on MET)Low risk of bias negative
LEAD-5 (vs Glargine), 2009    NCTliraglutide 1.8mginsulin glargine (add on SU+MET)Risk of bias negative
LEAD 1 (1.8 vs 1.2), 2009   liraglutide 1.8mgliraglutide 1.2mgnegative
LEAD 2 (1.8 vs 1.2), 2009   liraglutide 1.8mgliraglutide 1.2mgnegative
LEAD 4 (1.8 vs 1.2), 2009   liraglutide 1.8mgliraglutide 1.2mgnegative
Feinglos, 2005     liraglutide other dosesmetforminExploratory negative
LEAD-1 SU (1.2 vs rosiglitazone), 2009   liraglutide 1.2mgrosiflitazonesuggesting
LEAD-1 SU (1.8 vs rosiglitazone), 2009      NCTliraglutide other dosesrosiglitazone (add on SU)Low risk of bias suggesting
Pratley 1.2mg, 2010      NCTliraglutide 1.2mgsitagliptinRisk of bias suggesting
Pratley 1.8mg, 2010    NCTliraglutide 1.8mgsitagliptinLow risk of bias suggesting
lixisenatide
GETGOAL-L    NCTlixisenatideplacebo (add on basal insulin)Low risk of bias -
Ratner DRI6012, 2010      NCTlixisenatideplacebo (add on MET)Exploratory -
taspoglutide
Nauck 10 once weekly vs PBO, 2009      NCTtaspoglutide 10mg once weeklyplaceboExploratory suggesting
Nauck 20 every 2 weeks vs PBO, 2009   taspoglutide 20mg once every 2 weeksplacebosuggesting
Nauck 20 once weekly vs PBO, 2009   taspoglutide 20mg once weeklyplacebosuggesting
Ratner (20mg once weekly), 2010      NCTtaspoglutideplacebo (add on MET)Exploratory suggesting